Switzerland

Back to Search

International Partner Search

Innovation & Technology Offer

Development and Manufacture of lentiviral vectors

Country of Origin: Spain
Reference Number: TOES20170908002
Publication Date: 20 September 2017

Summary

This Spanish SME is a lentiviral specialized CDMO offering personalized solutions based on the review of customer´s requirements and lentivirus vector design and cloning.
The company is specialized in the manufacture of research, preclinical toxicology and GMP-grade lentiviral vectors.

The company is looking to collaborate with Biotech/Pharma or biotechnology dedicated companies with a genetic therapy pipeline, with the need of developing, producing or using lentivirus vectors.

Description

The company proposes herein a technology for the development and manufacture of Lentiviral vectors by using a new type of bioreactors in comparison with the classical static bioreactors.

The company´s bioreactor innovative technology allows obtaining relevant titter results comparing to other classical manufacturing technologies. Moreover, importantly, the company is developing both Upstream (USP) and Downstream (DSP) processes for a given batch.

Additionally, this innovation presents a greater scalability between different size bioreactors and allows working with several bioreactors in parallel.

The experience of more than two thousand lentiviral batches manufactured by the company made possible implementing this innovations within it´s manufacturing platform.

The company develops and manufactures lentiviral vectors from very early stages to the manufacture for preclinical toxicology or for advanced phases requiring GMP manufacture.

Advantages and Innovations

Comparing to other companies developing and manufacturing lentiviral vectors, this profile offers the following advantages: 
- Sealed as Excellence Centre by European Union.
- Own Lentivirus-based technology
- More than 2.000 lentiviral batches manufactured.
- iCELLis-nano bioreactor technology: Compatible equipment at R&D and GMP suites.
- USP+DSP (Upstream and Downstream Process Development
- Improved transient transfection method.
- Increased final yield compared with regular protocols.
- Capacities, capabilities and infrastructure to increase current capacity.

Stage Of Development

Already on the market

Stage Of Development Comment

The company has preclinic, clinic and commercial production capacity of this technology.

Requested partner

The company is looking to collaborate with Biotech/Pharma or biotechnology dedicated companies with a genetic therapy pipeline, and with the need of developing, producing or using lentivirus vectors with specific characteristics.

The company offers itself to develope and produce these lentiviral vectors.

Contact Profile Owner